Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...